ArticleCancer research2019
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- ARHGAP36 imposes a bifurcate activation of adherens junction and actomyosin to promote entosis.Cell death and differentiation · 2026Article
- Article
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- Ubiquitin-dependent degradation of p27Kip1 and p21Waf1/Cip1 by AMBRA1 ensures G1 and S phase progression and limits replication stress.Nucleic acids research · 2026Article
- How is rosette formation in brain tumours linked with cerebrospinal fluid spread?Brain tumor pathology · 2026Review
- Functional genomics for improving adoptive T-cell transfer therapies.Journal for immunotherapy of cancer · 2025Review
- Molecular and genetic characterization of sex-linked orange coat color in the domestic cat.Current biology : CB · 2025Article
- A forward genetic screen identifies potassium channel essentiality in SHH medulloblastoma maintenance.Developmental cell · 2025Article
- Aggressive Malignant Ossifying Fibromyxoid Tumor With a RareInternational journal of surgical pathology · 2025Review
- FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.Cancer research · 2025Article
- FOXR2 in cancer development: emerging player and therapeutic opportunities.Oncology research · 2025Review
- MYCN as an oncogene in pediatric brain tumors.Frontiers in oncology · 2025Review
- Recapitulating the immune microenvironment in pediatric brain cancer: preclinical modeling strategies.Frontiers in immunology · 2025Review
- Rodent models of tumours of the central nervous system.Molecular oncology · 2024Review
- The emerging field of viroimmunotherapy for pediatric brain tumors.Neuro-oncology · 2024Review
- TheInternational journal of molecular sciences · 2024Article
- Distinct mechanisms of PTEN inactivation in dogs and humans highlight convergent molecular events that drive cell division in the pathogenesis of osteosarcoma.Cancer genetics · 2023Article
- Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.Cancer research · 2022Article
- Ambra1 in cancer: implications for clinical oncology.Apoptosis : an international journal on programmed cell death · 2022Review
- FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.Cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 13 institutions in 4 countries.
Pauline J BeckmannMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Jon D LarsonMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Alex T LarssonMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Jason P OstergaardMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Sandra WagnerMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Eric P RahrmannMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-2369-0342
Ghaidan A ShamsanDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-0884-7540
George M OttoMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Rory L WilliamsMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-2605-5790
Jun WangTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Catherine LeeTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Barbara R TschidaMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Paramita DasMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Adrian M DubucDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Branden S MoriarityMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Daniel PicardDepartment of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0003-3375-6202
Xiaochong WuDivision of Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, Toronto, Ontario, Canada.
Fausto J RodriguezDivision of Neuropathology, Johns Hopkins Hospital, Baltimore, Maryland.
Quincy RosemarieMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0394-1573
Ryan D KrebsMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Amy M MolanMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Addison M DemerMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Michelle M FreesMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
Anthony E RizzardiDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Stephen C SchmechelDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Charles G EberhartDepartment of Pathology, Ophthalmology and Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 200 First Street Southwest, Rochester, Minnesota.
Robert J Wechsler-ReyaTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
David J OddeDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota.
Annie HuangDivision of Hematology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Michael D TaylorDivision of Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, Toronto, Ontario, Canada.
Aaron L SarverMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota.
David A LargaespadaMasonic Cancer Center, Department of Pediatrics, and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota. larga002@umn.edu.
University of Minnesota Medical Center · USUniversity of Minnesota · USDiscovery Institute · USBrain Tumour Research · GBBrigham and Women's Hospital · USCalifornia Institute of Technology · USCancer Research UK Cambridge Center · GBGerman Cancer Research Center · DEHospital for Sick Children · CAJohns Hopkins Hospital · USJohns Hopkins University · USMayo Clinic · USUniversity of Wisconsin–Madison · US
Funding
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3MProject 2: Cell Migration in Mechanically Complex MicroenvironmentsU54CA210190 · NCI · UNIVERSITY OF MINNESOTA · PI WOOD, DAVID KEVIN · 2016 to 2020
$10.0MMinnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2MSleeping Beauty for uncovering cancer genes in miceR01CA113636 · NCI · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW · 2006 to 2016
$2.5MModeling and microsystems approach to glioma invasionR01CA172986 · NCI · UNIVERSITY OF MINNESOTA · PI ODDE, DAVID J., ROSENFELD, STEVEN S · 2013 to 2017
$2.3MStem Cell Biology Training ProgramT32GM113846 · NIGMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2015 to 2019
$712kBioinformatics approaches to solve the "Missing Driver" problem in solid tumorsR50CA211249 · NCI · UNIVERSITY OF MINNESOTA · PI SARVER, AARON L · 2016 to 2020
$565kNCI NIH HHS R01 CA113636NCI NIH HHS R01 CA172986NCI NIH HHS R50 CA211249NCI NIH HHS T32 CA009138NCI NIH HHS U54 CA210190NIAID NIH HHS T32 AI083196NIGMS NIH HHS T32 GM113846
Abstract
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using
Indexed as
AnimalsBrain NeoplasmsCell Transformation, NeoplasticCerebellar NeoplasmsDNA Transposable ElementsFemaleForkhead Transcription FactorsGTPase-Activating ProteinsHumansMaleMedulloblastomaMembrane ProteinsMiceMice, NudeMutagenesis, InsertionalNeural Stem CellsARHGAP36 protein, humanDNA Transposable ElementsForkhead Transcription FactorsFOXR2 protein, humanFoxr2 protein, mouseGTPase-Activating ProteinsMEGF10, humanMegf10 protein, mouseMembrane Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.